Acute Myeloid Leukemia Accounts for About 1% of All Cancers During the Forecast Period

The market report titled ‘Global Acute Myeloid Leukemia Therapeutics Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.

Acute Myeloid Leukemia Therapeutics Market Drivers
The increasing prevalence of acute myeloid leukemia (AML) is one of the factor fueling the global acute myeloid leukemia therapeutics market.
For instance, according to American Cancer Society, in 2018, about 21,450 new cases of acute myeloid leukemia (AML) in the U.S.
According to American Cancer Society, in 2018, about 10,920 deaths from acute myeloid leukemia (AML).
In the U.S AML is one of the most common types of leukemia in adults. AML accounts for only about 1% of all cancers. Also,a according to Cancer Research UK, there are around 3,100 new acute myeloid leukaemia cases in the UK every year. Moreover, according to the Cancer Research UK, acute myeloid leukaemia accounts for less than 1% of all new cancer cases in UK.

Request for a free sample of the report - https://www.datamintelligence.com/research-report/acute-myeloid-leukaemia-therapeutics-market

Acute Myeloid Leukemia Therapeutics Market Size
Based on chemotherapy drugs the global market for acute myeloid leukemia therapeutics is broadly segmented as by cytarabine, clolar, gleevac, sprycel, fludara, oncaspar, nelarabine, and treanda.
In November 2018, AbbVie, have received the U.S. Food and Drug Administration (FDA) approval for VENCLEXTA (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Acute Myeloid Leukemia Therapeutics Market Regional Share
The global Acute Myeloid Leukemia Therapeutics market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa.
North America is dominating the global acute myeloid leukemia therapeutics market, due to the increasing regulatory approval for acute myeloid leukemia therapeutics.
For instance, in November 2018, Astellas Pharma Inc. have received the U.S. Food and Drug Administration (FDA) approved XOSPATA (generic name: gilteritinib) for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML). XOSPATA is an oral therapy and the first and only FLT3-targeting therapy to be approved.

Acute Myeloid Leukemia Therapeutics Market Company Trends
The increasing regulatory approval is one of the key factor driving the global acute myeloid leukemia therapeutics market.
In August 2017, Celgene Corporation and Agios Pharmaceuticals, Inc. have received approval for IDHIFA (enasidenib) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2). IDHIFA, is an oral targeted inhibitor of the IDH2 enzyme.
The major players include Sunesis Pharmaceuticals, Celgene Corporation, Eisai Co. Ltd, Clavis Pharma, Cephalon Inc, Ambit Biosciences Corporation, Genzyme Corporation, Bristol Myers Squibb, Johnson and Johnson, Pfizer, Novartis, and Roche.

Read more information about the research report - https://www.datamintelligence.com/research-report/acute-myeloid-leukaemia-therapeutics-market
Table of contents overview -
1. Acute Myeloid Leukemia Therapeutics Market – Methodology and Scope
2. Acute Myeloid Leukemia Therapeutics Market – Market Definition and Overview
3. Acute Myeloid Leukemia Therapeutics Market – Executive Summary
4. Acute Myeloid Leukemia Therapeutics Market – Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Acute Myeloid Leukemia Therapeutics Market – Industry Analysis
6. Acute Myeloid Leukemia Therapeutics Market – By Pipeline drugs
7. Acute Myeloid Leukemia Therapeutics Market – By Chemotherapy Drugs
8. Acute Myeloid Leukemia Therapeutics Market – By Chemotherapy Regimens
8.1. Introduction
9. Acute Myeloid Leukemia Therapeutics Market – By Region
9.1. North America
9.2. Europe
9.3. South America
9.4. Asia Pacific
9.5. Middle East and Africa
10. Acute Myeloid Leukemia Therapeutics Market – Competitive Landscape
11. Acute Myeloid Leukemia Therapeutics Market – Company Profiles
12. Acute Myeloid Leukemia Therapeutics Market – Premium Insights
13. Acute Myeloid Leukemia Therapeutics Market – DataM

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. This approach not only aligns the findings with historical data but also allows a highly justifiable forecast model.

This release was published on openPR.